Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The CooperCOO -1.61%89 EV-to-EBIT is 32.33 as of Jul. 17, 2026, which is 9% below its 10-year median of 35.58. GuruFocus rates COO with a GF Score™ of 89/100 and a GF Value™ of $101.24 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 466 Medical Devices & Instruments companies, The Cooper ranks worse than 74.25% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
The Cooper's Enterprise Value for the quarter that ended in Apr. 2026 was $14,582 Mil.
The Cooper's EBIT for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $506 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The Cooper EV-to-EBIT Related Terms
The Cooper EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for The Cooper's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, The Cooper's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
The Cooper EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, The Cooper's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where The Cooper's EV-to-EBIT falls into.
The Cooper's current Enterprise Value is $16,348 Mil.
The Cooper's EBIT for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $506 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The Cooper (COO) has a EV-to-EBIT of 32.33 as of Jul. 17, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on The Cooper and its competitors. This is near median its historical median of 35.58. Over the past decade, The Cooper's EV-to-EBIT has ranged from 21.44 to 68.56. According to the industry distribution chart, The Cooper ranks #346 out of 466 companies in the Medical Devices & Instruments industry, placing it in the top 74.2%.
Is The Cooper's EV-to-EBIT too high?
The Cooper's current EV-to-EBIT of 32.33 is near median its 10-year median of 35.58. Over the past 10 years, this metric has ranged from a low of 21.44 to a high of 68.56. The Medical Devices & Instruments industry median EV-to-EBIT is 18.46. The Cooper's value of 32.33 is 75.1% above this industry median. Based on the distribution chart, The Cooper ranks #346 out of 466 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, The Cooper has a GF Score™ of 89/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does The Cooper's EV-to-EBIT compare to SOLV and ALGN?
According to the Medical Devices & Instruments industry distribution chart, The Cooper ranks #346 out of 466 companies for EV-to-EBIT. This places The Cooper in the lower half of its industry. The industry median EV-to-EBIT is 18.46. The Cooper's value of 32.33 is 75.1% above this benchmark. Historically, The Cooper's own EV-to-EBIT has ranged from 21.44 to 68.56 over the past decade. While the company's 10-year median is 35.58 vs. the industry median of 18.46, The Cooper has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.46, based on 466 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. The Cooper's current EV-to-EBIT of 32.33 is 75.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on The Cooper and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. The Cooper's current EV-to-EBIT is 32.33, which is near median its own 10-year median of 35.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The Cooper stock overvalued right now?
Based on GuruFocus' analysis, The Cooper (COO) is currently considered Modestly Undervalued. The stock's GF Value™ is $101.24, compared to a current price of $71.92 — trading 29% below its estimated fair value. The current EV-to-EBIT is 32.33, which is near median its 10-year median of 35.58 and 75.1% above the Medical Devices & Instruments industry median of 18.46. The Cooper's overall GF Score™ is 89/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For The Cooper (COO), the current EV-to-EBIT is 32.33 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is The Cooper (COO) Overvalued in 2026?
Based on GuruFocus' analysis, The Cooper stock appears to be undervalued.
The current stock price of $71.92 is trading 29% below its estimated GF Value™ of $101.24.
GuruFocus considers The Cooper to be Modestly Undervalued.
Key valuation signals for COO:
EV-to-EBIT: 32.33 (near median its 10-year median of 35.58)
GF Value™: $101.24 vs. price of $71.92 (29% below fair value)
Industry Position: 75.1% above the Medical Devices & Instruments median (#346 of 466)
No single metric tells the full story. See the COO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CooperCompanies is one of the largest eyecare companies in the US. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the US contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the US, and controls 17% of the US IUD market.
89GF Score
Get the complete analysis for COO
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
COO has been successfully added to your 
